(Q34990624)

5 August 2017

1 reference

title

High-density lipoproteins and atherosclerosis. (English)

1 reference

5 August 2017

1 reference

1 reference

Daniel J Rader

1

1 reference

PubMed ID

12419482

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

American Journal of Cardiology

5 August 2017

1 reference

5 August 2017

90

1 reference

5 August 2017

62i-70i

1 reference

5 August 2017

8A

1 reference

High-density lipoprotein--the clinical implications of recent studies

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Familial hypoalphalipoproteinemia in premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic Rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Retrovirus-mediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

ABC1: connecting yellow tonsils, neuropathy, and very low HDL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Overexpression of human lecithin:cholesterol acyltransferase in mice offers no protection against diet-induced atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Scavenger receptor BI--a cell surface receptor for high density lipoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Plasma high density lipoproteins. Metabolism and relationship to atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

An in vivo evaluation in man of the transfer of esterified cholesterol between lipoproteins and into the liver and bile.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

A Low Prevalence of Coronary Heart Disease among Subjects with Increased High-Density Lipoprotein Cholesterol Levels, Including Those with Plasma Cholesteryl Ester Transfer Protein Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Evidence for reverse cholesterol transport in vivo from liver endothelial cells to parenchymal cells and bile by high-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Relevance to regression of atherosclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

HDL and the inflammatory response induced by LDL-derived oxidized phospholipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Antioxidative activity of high density lipoproteins in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Inhibition of VCAM-1 Expression in Endothelial Cells by Reconstituted High Density Lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

HDL-Induced Prostacyclin Release in Smooth Muscle Cells Is Dependent on Cyclooxygenase-2 (Cox-2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Protein composition determines the anti-atherogenic properties of HDL in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Apolipoprotein specificity for lipid efflux by the human ABCAI transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

High-density lipoprotein subclasses and apolipoprotein A-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Remodelling of high density lipoproteins by plasma factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

The role of hepatic lipase in lipoprotein metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Reduced HDL2 cholesterol subspecies and elevated postheparin hepatic lipase activity in older men with abdominal obesity and asymptomatic myocardial ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Low hepatic lipase activity is a novel risk factor for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Plasma lipoproteins in familial hepatic lipase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

A novel endothelial-derived lipase that modulates HDL metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Cloning of a unique lipase from endothelial cells extends the lipase gene family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Endothelial lipase: a new member of the triglyceride lipase gene family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Does exercise increase HDL cholesterol in those who need it the most?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Role of fibrates in the management of hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Treatment of hyperlipidemia with combined niacin-statin regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902635-8

10.1016/S0002-9149(02)02635-8

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12419482